All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Expert Commentary: Insights into Cancer Mutation Patterns

April 4th 2024

Researchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.

CAN-2409 Plus Valacyclovir Generates Positive Phase 2 Survival Results in PDAC

April 4th 2024

Positive phase 2 findings for CAN-2409 plus valacyclovir in pancreatic ductal adenocarcinoma have been reported.

Tomivosertib Development in Frontline NSCLC Ending After Findings from KICKSTART Trial

April 4th 2024

Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.

Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant Ovarian Cancer

April 4th 2024

Debra L. Richardson, MD, FACS, FACOG, expands on results with upifitamab rilsodotin in platinum-resistant high-grade serous ovarian cancer.

Koo Looks to the Future With PSMA PET Imaging in Prostate Cancer

April 4th 2024

Phillip J. Koo, MD, highlights future directions regarding PSMA PET imaging and key takeaways from a presentation he gave on the precision imaging tool.

Metastasis-Directed Radiotherapy Represents Significant Advancement in Prostate Cancer

April 4th 2024

Daniel Spratt, MD, discusses how evolving radiation therapy techniques in prostate cancer can reduce adverse effects and shorten treatment courses.

Recommendations Further Aid in Elucidating the Role of PSMA PET Imaging in Prostate Cancer

April 3rd 2024

Phillip J. Koo, MD, discusses how PSMA PET will be used in clinical trials, the RADAR VI guidelines for using the precision imaging tool, and more.

SABR Leads to Local Control in Primary RCC Without Surgery

April 3rd 2024

Stereotactic ablative body radiotherapy elicited high local control rates in patients with renal cell carcinoma who did not undergo surgical resection.

Breaking Down the Utility of Vepdegestrant in First-Line ER+/HER2– Breast Cancer

April 3rd 2024

Carlos L. Arteaga, MD, discusses the utility of vepdegestrant alone or in combination in patients with ER-positive, HER2-negative advanced breast cancer.

Insights, Innovations, and Challenges Ahead in the Treatment of Urothelial Carcinoma

April 3rd 2024

Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.

Fox Chase Cancer Center and Lewis Katz School of Medicine at Temple University Surgeons Elected to Education Committee of the Association for Academic Surgery

April 3rd 2024

Anthony Villano, MD, and Joceline Vu, MD, were recently elected members of the Education Committee of the Association for Academic Surgery.

VBI-1901 Elicits Disease Control in Recurrent Glioblastoma

April 3rd 2024

The cancer vaccine immunotherapeutic VBI-1901 generated disease control in patients with recurrent glioblastoma.

European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS

April 3rd 2024

The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.

Segmenting the Utility of ADCs in NSCLC: How These Agents Are Affecting Second-Line Standards

April 3rd 2024

Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.

Tripathy Outlines Where the HER2+ Early-Stage Breast Cancer Landscape Stands

April 3rd 2024

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024

NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.

Scott Armstrong Named Senior Vice President for Drug Discovery and Chief Research Strategy Officer at Dana-Farber

April 2nd 2024

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.

Preliminary Data Hint at PFS Benefit With Personalized Neoantigen Vaccine in Metastatic MSS CRC

April 2nd 2024

Treatment with GRANITE showed early signals of activity following frontline induction chemotherapy in metastatic microsatellite stable colorectal cancer.

FDA to Review Zanidatamab BLA for HER2+ Metastatic Biliary Tract Cancer

April 2nd 2024

A rolling BLA for zanidatamab in previously treated, HER2-positive, advanced biliary tract cancer has been submitted to the FDA.

China’s NMPA Grants Priority Review to Sintilimab Plus Fruquintinib in pMMR/Non–MSI-H Advanced Endometrial Cancer

April 2nd 2024

The new drug application for sintilimab plus fruquintinib has been granted priority review by the NMPA for pMMR/non-MSI-H advanced endometrial cancer.